August 20, 2024 - 🧬 [nGram] Today’s Neurology Scoop: Alzamend Neuro's Phase II Trial, SciSparc's Enrollment, Alpha Cognition's Patent

1. Alzamend Neuro partners with Massachusetts General Hospital for a Phase II clinical trial of AL001 for PTSD

   • Alzamend Neuro collaborates with Massachusetts General Hospital to conduct a Phase II clinical trial of AL001 for PTSD.
   • The trial aims to compare brain lithium levels from AL001 to commonly marketed lithium salts in PTSD patients.
   • Dr. Ovidiu Andronesi from Harvard University will be the principal investigator.
   • The study seeks to meet regulatory safety standards through the FDA's Section 505(b)(2) pathway.
   Read more
   
   

2. SciSparc announces enrollment of the first five patients in the clinical trial of its innovative SCI-210 treatment

   • SciSparc has enrolled the first five patients in its clinical trial for SCI-210, targeting autism spectrum disorder (ASD).
   • The trial is being conducted at Soroka Medical Center in Israel and will include 60 subjects aged 5-18 over 20 weeks.
   • SCI-210 combines cannabidiol (CBD) and CannAmide to alleviate ASD symptoms, compared to standard CBD monotherapy.
   • The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community (ABC-C), Clinical Global Impressions-Improvement (CGI-I), and effective therapeutic dose.
   Read more
   
   

3. Alpha Cognition receives notice of allowance for composition-of-matter patent for Zunveyl for mild to moderate Alzheimer’s disease

   • Alpha Cognition Inc. has received a Notice of Allowance from the USPTO for patent application No. 18/463,157.
   • The patent covers a novel crystalline solid form of Zunveyl, adding to existing patents for the drug.
   • This patent provides protection for a second commercially viable form of Zunveyl, extending its patent life in the U.S. through 2042.
   • Zunveyl is an FDA-approved acetylcholinesterase inhibitor for mild to moderate Alzheimer’s disease, with minimal gastrointestinal side effects.
   Read more
   
   

4. Aruna Bio announces issuance of U.S. patent for method of use for neural exosomes used to reduce inflammation in the brain

   • Aruna Bio has been granted a U.S. patent for its lead program, AB126, which uses neural exosomes to treat neuro-inflammatory diseases.
   • AB126 is derived from proprietary neural stem cells and has shown efficacy in reducing brain inflammation.
   • The patent covers multiple neurodegenerative diseases, including Alzheimer's, Parkinson's, ALS, and more.
   • Various administration routes are included in the patent, such as intravenous, intranasal, and direct brain delivery.
   Read more